English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 January 2021, 08:00 HKT/SGT
Share:
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40
The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors

HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308



Topic: Press release summary Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Peapack-Gladstone Financial Corp (NASDAQ: PGC) Second Quarter 2025 Financial Results  
July 22, 2025 19:44 HKT/SGT
Military Metals Announces Grab Sample Results up to 40.6% Antimony and 106.5 gpt Gold from Stockpile of Historically Mined Material at West Gore Antimony-Gold Project, Nova Scotia  
July 22, 2025 19:39 HKT/SGT
35th Hong Kong Book Fair attracts some 900,000 visits despite typhoon  
July 22, 2025 19:22 HKT/SGT
Satellite Direct-to-Device: CaoCao Becomes the World's First to Embed LEO Satellite Communication Services in the Robotaxi Platform  
July 22, 2025 18:53 HKT/SGT
InfoComm India 2025 Visitor Registration Opens Strong Amidst Surging Demand for AI and Immersive AV  
July 22, 2025 18:44 HKT/SGT
Mitsubishi Motors to Terminate Its Joint Venture Partnership with Shenyang Aerospace Mitsubishi Motors Engine Manufacturing  
Tuesday, July 22, 2025 4:00:00 PM
Capital Markets Malaysia Expands Simplified ESG Disclosure Guide with a GHG Emission Calculator for SMEs  
July 22, 2025 14:15 HKT/SGT
CMS Collaborates with SGX to Explore New Paradigms for Industrial Globalization and Pharmaceutical Expansion Overseas across Emerging Markets  
July 22, 2025 13:00 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025  
Tuesday, July 22, 2025 10:56:00 AM
ASEAN Ceramics & ASEAN Stone Open Doors this October in Bangkok, Thailand  
July 22, 2025 10:10 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575